FGF19 and metabolic dysfunction-associated steatohepatitis: Among these small molecules, bile acids are of particular interest in NASH given their potent roles in mediating metabolic functions [48], as illustrated by the fact that several agonists of the bile acid receptor—Farnesoid X receptor (FXR) and its downstream target FGF19 are in phase I and II trials in treating NASH [49,50,51].